The Market Withdrawal
In September 2024 Pfizer voluntarily withdrew Oxbryta, a treatment for sickle cell disease, from markets worldwide after post-marketing data indicated that its benefits no longer outweighed its risks — specifically, a higher rate of vaso-occlusive crises (severe pain episodes) and deaths among patients taking it compared with placebo. A voluntary withdrawal of an approved drug for a safety signal like this is significant.
Adverse-event data cited in the litigation reported hundreds of deaths associated with the drug, though association in a reporting system is not the same as proven causation.
The Lawsuits
Patients and families have sued Pfizer, alleging the company failed to adequately investigate and disclose the drug’s risks and that Oxbryta caused serious complications, including strokes and deaths. An early wrongful-death case reached a confidential settlement, and in 2025 a retired judge was appointed to mediate the broader litigation, a step courts often take to explore resolution as cases consolidate.
These remain allegations; the withdrawal itself is documented, but whether the drug caused a given patient’s outcome is the contested question.
What Patients Should Know
Anyone who took Oxbryta should follow their hematologist’s guidance on alternatives; this page is legal-news coverage, not medical advice. For a claim, the evidence is the prescription history and medical records tying an injury to the drug. There is no broad approved settlement fund yet.
Before You Act
Thinking About Filing a Claim?
Most plaintiff lawyers offer a free initial consultation and work on contingency, meaning no fee unless there is a recovery. LawsuitWatch is not a law firm: we publish explainers, and we do not provide legal advice, representation or referrals. Your state bar directory is the reliable place to find and verify a lawyer.
Oxbryta Lawsuit: The Withdrawn Sickle Cell Drug: Frequently Asked Questions
Answers to the most common questions about this case and your legal options.
Why was Oxbryta withdrawn?
Pfizer withdrew it in September 2024 after post-marketing data showed a higher rate of vaso-occlusive pain crises and deaths versus placebo, indicating the benefits no longer outweighed the risks.
What do the Oxbryta lawsuits claim?
That Pfizer failed to adequately investigate and disclose the drug's risks and that Oxbryta caused serious harm, including strokes and deaths. These are allegations not yet proven.
Is there an Oxbryta settlement?
An early wrongful-death case settled confidentially, and a mediator was appointed for the broader litigation in 2025. There is no broad approved settlement fund yet.
Legal Disclaimer
This article is general legal information, not legal advice, and does not create an attorney-client relationship. Case status, eligibility criteria, and any amounts described are as reported at the date shown and may change. Consult a licensed attorney in your jurisdiction about your own situation.